1. Tziomalos K. Secondary hypertension: novel insights. Curr Hypertens Rev 2020;16:11.
2. Williams B, Mancia G, Spiering W, et al. 2018 practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Press 2018;27:314–340.
3. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014;35:1245–1254.
4. Muiesan ML, Rizzoni D, Salvetti M, et al. Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens 2002;20:1439–1444.
5. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016;101:1889–1916.
6. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293–2300.
7. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004;89:1045–1050.
10. Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management: a clinical approach. Endocrinol Metab Clin North Am 2019;48:681–700.
12. Rossi GP, Belfiore A, Bernini G, et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 2007;25:1433–1442.
13. Morera J, Reznik Y. Management of endocrine disease: the role of confirmatory tests in the diagnosis of primary aldosteronism. Eur J Endocrinol 2019;180:R45–R58.
15. Rossitto G, Amar L, Azizi M, et al. Subtyping of primary aldosteronism in the AVIS-2 study: assessment of selectivity and lateralization. J Clin Endocrinol Metab 2020;105:dgz017.
16. Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol 2021;9:876–892.
17. Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017;5:689–699.
23. Hackam DG, Duong-Hua ML, Mamdani M, et al. Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J 2008;156:549–555.
24. Losito A, Gaburri M, Errico R, Parente B, Cao PG. Survival of patients with renovascular disease and ACE inhibition. Clin Nephrol 1999;52:339–343.
25. Prince M, Tafur JD, White CJ. When and how should we revascularize patients with atherosclerotic renal artery stenosis? JACC Cardiovasc Interv 2019;12:505–517.
26. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med 2019;381:552–565.
27. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005;366:665–675.
28. Sbardella E, Grossman AB. Pheochromocytoma: an approach to diagnosis. Best Pract Res Clin Endocrinol Metab 2020;34:101346.
29. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003;88:2656–2666.
33. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. Lancet 2015;386:913–927.
34. Lahera Vargas M, da Costa CV. Prevalence, etiology and clinical findings of Cushing's syndrome. Endocrinol Nutr 2009;56:32–39.
36. Pecori Giraldi F, Pivonello R, Ambrogio AG, et al. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) 2007;66:251–257.
37. Moro M, Putignano P, Losa M, Invitti C, Maraschini C, Cavagnini F. The desmopressin test in the differential diagnosis between Cushing's disease and pseudo-Cushing states. J Clin Endocrinol Metab 2000;85:3569–3574.
38. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006;367:1605–1617.
40. Ferriere A, Tabarin A. Cushing's syndrome: treatment and new therapeutic approaches. Best Pract Res Clin Endocrinol Metab 2020;34:101381.
41. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011;58:811–817.